Annette H. Boers-Galema
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry.
Journal: Atherosclerosis
Published: January 23, 2025
PCSK9 inhibitor experiences and preferences of patients and healthcare professionals in decision-making: A mixed methods study.
Journal: Atherosclerosis
Published: June 04, 2024
First clinical experiences with inclisiran in a real-world setting.
Journal: Journal of clinical lipidology
Published: May 07, 2023
Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry.
Journal: Atherosclerosis
Published: December 31, 2022
The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
Journal: Atherosclerosis
Published: July 12, 2019
No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 28, 2018
Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience.
Journal: Clinical pharmacology and therapeutics
Published: June 14, 2018
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH.
Journal: Journal of clinical lipidology
Published: December 17, 2017
Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
Journal: Journal of clinical lipidology
Published: December 28, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026